| Indication |
Phase |
Sample Size |
Study Design |
| Acute Exacerbations of Chronic Bronchitis |
4 |
250 |
Multi-center,
randomized, double-blind, positive controlled, parallel group
study |
| Anti-bacterial |
2 |
30 |
Double-blind,
randomized, placebo-controlled, sequential design study |
| Chronic Hepatitis C |
2 |
100 |
Randomized, double-blind, placebo-controlled, stepwise, sequential, dose-escalation |
| Healthy Subjects (Anti-inflammatory) |
1 |
16 |
Double-blind, placebo-controlled intervention study |
| Healthy Subjects (Anti-bacterial) |
1 |
100 |
Double-blind,
randomized, controlled study with six sequential cohorts |
| Healthy Subjects (Anti-bacterial) |
1 |
30 |
Double-blind,
randomized, placebo-controlled study with two cohorts |
| Healthy Subjects (Anti-fungal) |
1 |
100 |
Double-blind,
placebo-controlled, sequential, ascending, single, multiple
loading and maintenance doses study |
| Healthy Subjects (Anti-fungal) |
1 |
150 |
Two-tier randomized,
double-blind, placebo- and active-controlled, parallel design
study |
| Healthy Subjects (Anti-fungal) |
1 |
30 |
Open-label study |
| Healthy Subjects (Pain and Inflammation) |
1 |
72 |
A randomized, double-blind, single-center, placebo-controlled, single-ascending-dose study |
| Healthy Subjects (Pain and Inflammation) |
1a |
54 |
A single-dose, two-stage pharmacokinetic and pharmacodynamic study |
| Healthy Subjects (Skin Infection) |
4 |
15 |
Single and multiple
dose, open-label study |
| Healthy Subjects (Sepsis) |
1 |
10 |
Single center,
non-randomized, open-label study |
